Although an experimental precision drug slowed progression of lung cancer in a late-stage trial, the company’s shares fell as much as 6% as analysts said the benefits may not be as pronounced as hoped.
A thyroid cancer safety signal was raised by the EU’s drugs watchdog last month over several Novo Nordisk (NOVOb.CO) products including semaglutide, which is used in popular diabetes and obesity medicines Ozempic and Wegovy.
Europe’s pharmaceutical sector could lose out to increased competition from emerging markets, China and the U.S. in terms of research and innovation if a proposed European Union health package is not amended, its key industry group said on Thursday.
AstraZeneca has decided to stop a mid-stage trial for the asthma medication elarekibep after data from a non-clinical toxicology study revealed inflammation-related lung tissue damage, according to an announcement Wednesday by Pieris Pharmaceuticals Inc., which licensed the inhaled IL-4 receptor alpha inhibitor to the British pharma.
Drugmaker AstraZeneca is drafting a plan to spin off its China business, and listing a separate unit in Hong Kong is being viewed as an option, the Financial Times reported on Sunday.
A week after licensing a novel gene therapy from Kate Therapeutics to treat X-linked myotubular myopathy, Astellas Wednesday announced a strategic collaboration with San Diego- and China-based Cullgen to develop multiple targeted protein degraders.
The Anglo-Swedish drugmaker said the long-term agreement with Massachusetts-based Vanguard Renewables would enable it to transition to biogas from natural gas and cut its emissions across its U.S. research and manufacturing sites.
AstraZeneca said on Friday it had signed an agreement with Quell Therapeutics potentially worth more than $2 billion to develop cell therapies that could cure autoimmune diseases.
The advisers voted unanimously in favor of using the antibody, nirsevimab, in newborns and infants to prevent infections in their first RSV season.
The American Society of Clinical Oncology 2023 annual meeting kicked off Friday in Chicago, and BioSpace’s Greg Slabodkin spoke with leading biopharma analysts about the most-anticipated ASCO abstracts.